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Abstract 
The HIV care continuum is a framework that models the dynamic stages of HIV care. The continuum consists of five 
main steps, which, at the population level, are depicted cross-sectionally as the HIV treatment cascade. These steps 
include diagnosis, linkage to care (LTC), retention in care (RiC), adherence to antiretroviral therapy (ART), and viral sup-
pression. Although the HIV treatment cascade is represented as a linear, unidirectional framework, persons living with 
HIV (PLWH) often experience the care continuum in a less streamlined fashion, skip steps altogether, or even exit the 
continuum for a period of time and regress to an earlier stage. The proportion of PLWH decreases at each successive 
step of the cascade, beginning with an estimated 86% who are diagnosed and dropping dramatically to approxi-
mately 30% of PLWH who are virally suppressed in the United States (US). In this current issues review, we describe 
each step in the cascade, discuss targeted interventions that address weak points in the continuum, review domestic 
and international policies that help shape and direct HIV care strategies, and conclude with recommendations and 
future directions for HIV providers and policymakers. While we primarily examine issues related to domestic HIV care 
in the US, we also discuss international applications of the continuum in order to provide broader context.
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Review
Introduction
The HIV care continuum is an internationally-recognized 
framework, initially depicted in the United States (US) 
to represent HIV care as a progression from testing to 
engagement in medical care, antiretroviral therapy (ART) 
treatment, and, ultimately, suppression of the virus [1–4]. 
Although the terms “cascade” and “continuum” are often 
used interchangeably, in this review we use continuum 
to refer to dynamic and bidirectional navigation of the 
spectrum of HIV care engagement at an individual level, 
while treatment cascade examines a static, cross-sec-
tional representation of these steps at a population level. 
The HIV care continuum gained considerable visibility 
in the US in 2013 due to the formation of the HIV care 
continuum initiative, created through Executive Order 
by the President, which prioritizes the establishment of 
a set of national indicators for HIV care [5]. These ten 
indicators, as detailed in the recently updated National 
HIV/AIDS Strategy (NHAS) for the US, reflect quantifi-
able 5-year goals for 2020 [6]. The updated NHAS syn-
thesizes recommendations from the HIV care continuum 
initiative, incorporates findings from contemporary HIV/
AIDS research, and highlights changes in HIV healthcare 
due to the passage of the Affordable Care Act (ACA) [6].
Although the Centers for Disease Control and Preven-
tion (CDC) emphasize the importance of universal HIV 
testing at one end of the continuum and viral suppres-
sion at the other [1], researchers have drawn attention 
to the fact that steps in the middle of the continuum—
linkage to care (LTC) and retention in care (RiC)—are 
vital in securing optimal health outcomes [3, 7, 8]. This 
is perhaps best exemplified in the national estimates of 
the number of persons living with HIV (PLWH) who fall 
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at each end of the continuum: Whereas 86% of all PLWH 
in the US know that they are HIV-infected, an estimated 
30% actually achieve viral suppression [1, 2]. The HIV 
treatment cascade is usually represented as a unidirec-
tional series of five steps, including HIV diagnosis, LTC, 
engagement/retention in care, ART initiation and adher-
ence, and viral suppression [1, 3, 7]. However, some 
researchers have suggested that the true nature of HIV 
care is often nonlinear, given that PLWH may iteratively 
transition in and out of treatment [3, 9, 10]. Moreover, 
a model developed by Gardner and colleagues sug-
gests that an improvement in just one step of the treat-
ment cascade would have little effect on the ultimate 
goal of viral suppression, underscoring how imperative 
it is to facilitate efficient and effective passage of PLWH 
through each step [2].
With continued advances in HIV treatment and 
increased knowledge regarding best practices for care, 
there is no justifiable reason that PLWH should receive 
suboptimal linkage to and retention in care. Yet, the 
majority of PLWH in the US do not have their disease 
adequately managed, and, every year, approximately 
50,000 people are newly infected with HIV [11]. In this 
current issues review, we focus on successive steps of the 
HIV treatment cascade in which we provide summaries 
of each component, describe data monitoring strategies 
for accurately accounting for PLWH at each step, and 
discuss effective interventions specific to each phase. We 
also examine recent changes in US healthcare policy and 
how these changes interface with the HIV continuum, 
and we offer recommendations and future directions for 
HIV providers and policymakers. Although the focus 
of this review is the HIV care continuum as applied to 
PLWH in the US, we will also provide international con-
text, as indicated.
Diagnosis
Entry into the HIV treatment cascade begins with diagno-
sis. Current CDC guidelines recommend that healthcare 
professionals offer every patient between the ages of 13 
and 64 an HIV test at least once, as an initiative to make 
HIV screening a routine rather than risk-based practice 
in healthcare settings [12]. HIV testing has never been 
more efficient or patient-friendly, as rapid test results can 
be available in under half an hour [13]; thus, integrat-
ing testing into routine health care visits is not a difficult 
task. Moreover, home testing is now available, providing 
individuals with enhanced access and control in learning 
their HIV serostatus. The US Preventative Services Task 
Force (USPSTF) has guidelines similar to the CDC’s for 
routine HIV testing [14], which has important implica-
tions for insurance coverage and payment for this screen-
ing test. However, it is estimated that approximately one 
in eight individuals who are HIV-positive are not aware 
of their serostatus, leaving ample room for improvements 
in domestic HIV testing and diagnosis [11]. This is not 
only a public health risk as it increases the probability that 
PLWH will unknowingly transmit HIV to others, but it is 
also detrimental to individual medical outcomes, as late 
diagnosis is associated with increased morbidity and mor-
tality [15]. Further, Skarbinski and colleagues estimate that 
91.5% of all new HIV infections are attributable to PLWH 
who are either undiagnosed or who are diagnosed but 
not retained in care [16]. In order to address these weak-
nesses in the continuum, one of the key goals set forth 
by the 2020 NHAS is to increase the number of PLWH 
who are aware of their status to 90% [6]. The Joint United 
Nations Programme on HIV/AIDS (UNAIDS) recently 
set international goals for 2020 termed the “90–90–90 
target,” which aim to increase the number of PLWH who 
know their serostatus to 90%, and, among those who are 
diagnosed, to increase the percentage who are prescribed 
ART to 90% [17]. Likewise, among PLWH who are both 
diagnosed and on ART, the 90–90–90 target aims for 90% 
of PLWH to achieve and maintain viral suppression [17]. 
In response to the 90–90–90 target initiative, five cities 
shared their continuum of care data at the 21st Interna-
tional AIDS Conference, held in Durban, South Africa 
on July 18–22, 2016. [18]. These cities included San Fran-
cisco, California; Denver, Colorado; Amsterdam, Neth-
erlands; Paris, France, and Kyiv, Ukraine, all of which 
have joined the global Fast-Track Cities Initiative that 
seeks to fulfill UNAIDS targets in urban areas with high 
HIV burdens [18]. In these fast-track cities, the percent-
age of PLWH who know their serostatus ranges from 51% 
in Kyiv to 93% in Amsterdam and San Francisco [18]. At 
the country and province levels, the US falls somewhere 
in the middle range, above British Columbia but below 
Denmark and Australia [19]. These numbers underscore 
the variability that exists even at the entry point of the 
continuum.
For low-income individuals in the US, Medicaid is their 
most common source of health coverage. As originally 
written, the ACA would have made routine HIV testing 
a universally-covered preventative screening measure; 
however, unequal Medicaid expansion has led to state-
level variation in reimbursable routine HIV testing [20]. 
Currently, just 34 states cover routine HIV testing, while 
16 cover only “medically necessary” HIV testing, which 
is defined by the state [20]. Notably, the states that do 
not offer reimbursable routine HIV testing are predomi-
nantly the ones with the highest HIV infection rates, and 
they are overwhelmingly found in the South [6, 20, 21]. 
This coverage disparity may bar individuals from getting 
tested, and it ultimately prevents PLWH who are una-
ware of their serostatus from receiving treatment.
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Linkage to care
Linkage to care (LTC) is the second step in the HIV 
care continuum. The CDC and Institute of Medicine 
(IOM) both define LTC as a period of three months or 
less between documentation of diagnosis and initiation 
of medical treatment with an HIV care provider/pre-
scriber [1, 22]. The virtue of using a standard indicator 
is that it enables coordination among data tracking sys-
tems and facilitates policy analysis [22]; however, state 
reporting practices for reporting HIV diagnosis in the 
US vary, making it difficult to establish a standard base-
line for measurement purposes [23, 24]. It is even more 
difficult to compare LTC rates among countries because 
there are multiple statistical “back calculation” methods 
used to estimate the number of undiagnosed PLWH. 
[25]. According to a recent systematic review of the lit-
erature, outside of the US, only the countries of Georgia, 
Denmark, and Australia and the Canadian province of 
British Columbia have population data at all steps of the 
continuum. [25].
Although viral suppression is achieved more quickly 
if ART is started within three months of diagnosis [26], 
estimates of the proportion of PLWH who are linked 
to care within 3 months in the US are between 59% [2] 
and 80% [1]. In light of low LTC estimates, the updated 
NHAS has set a 2020 goal of 85% of PLWH who are 
linked to care within 1 month of diagnosis, rather than 
3 months, an ambitious target [6]. In other high-income 
countries and provinces, LTC proportions are higher, 
although none reach the targeted 85%. In British Colum-
bia, between 61 and 67% of PLWH who are aware of their 
serostatus are linked to care, while estimates of LTC per-
centages in Denmark and Australia are higher, at 78% of 
PLWH in Australia and 81% in Denmark [19, 27]. This 
exemplifies the fact that even in high-income regions 
with universal health care systems, like British Columbia 
and Denmark, many PLWH drop out of the continuum 
before they have even received care. In low-income coun-
tries LTC proportions are appreciably lower, although 
estimates are derived from targeted intervention data 
rather than population-based data. In these countries, it 
is common for PLWH to delay treatment for several years 
until the disease has rapidly progressed [28]. For exam-
ple, the proportion of PLWH linked to care in Kenya is 
42% [29] and in South Africa, 37% [30].
Several multi-site studies have developed strategies to 
facilitate LTC. For example, although created for the pur-
pose of testing and linking drug users to HIV care, the 
seek, test, treat, and retain (STTR) data collection and 
harmonization initiative is an HIV care model that is 
broadly applicable to many vulnerable populations [31]. 
As the authors discuss, what makes this model successful 
for HIV care is that it is built around a specific subgroup 
(e.g., drug users) and involves the collaboration of an 
interdisciplinary, multi-site team. Further, data interop-
erability is ensured through the use of standardized sur-
veys and questionnaires which collect data on a number 
of measures, such as drug and alcohol use, mental health, 
and HIV testing history [31]. By streamlining the strat-
egy’s approach and standardizing data collection and 
measurement techniques, the STTR Initiative facilitates 
coordinated research that, in turn, helps identify at-risk 
populations and link them to care [31]. Similarly, the 
multi-site access to care (A2C) initiative was developed 
for a specific subgroup—those living in poverty—and it 
expands on the HIV care continuum, primarily LTC [32]. 
In addition to using a set of quantifiable indicators, A2C 
also collects qualitative case studies to fully capture the 
experiences of staff members at each program site [32]. 
Further, A2C includes a cost-analysis component, which 
is especially useful for sites who may not have many 
resources. The STTR and A2C programs exemplify how 
LTC strategies may be developed in such a way that they 
address the needs of the target population, while also 
maximizing the resources available to the provider site(s).
Retention
There is a lack of consensus about how to best measure 
retention, or continuity, in HIV care. While the IOM, 
NHAS, and CDC define HIV retention in care (RiC) as 
the proportion of PLWH who have “two or more visits 
for routine HIV medical care in the preceding 12 months 
at least three months apart” [22], these measures only 
account for adherence to scheduled medical appoint-
ments and not for missed or cancelled appointments [3]. 
Thus, it is recommended that any measure of RiC include 
at least two indicators—one for kept appointments and 
one for missed appointments—as they appear to provide 
complementary information [3, 33]. In fact, the num-
ber of missed appointments is a significant predictor in 
measuring clinical outcomes. Several studies have found 
that the number of missed medical appointments is sig-
nificantly associated with higher viral loads and lower 
CD4 counts [4, 34]. Moreover, national racial dispari-
ties in HIV health outcomes [24, 35] may actually belie 
the presence of other factors. For example, in a multi-site 
trial, Zinski and colleagues found that the lower propor-
tion of viral suppression found among African Ameri-
cans in comparison to other racial groups loses statistical 
significance when accounting for the number of missed 
visits [36].
Compared to other high-income areas of the world, the 
US has the lowest proportion of PLWH who are retained 
in care. In British Columbia, 57% of diagnosed PLWH 
are retained in care [19, 27], and 75 and 76% are retained 
in Denmark and Australia, respectively [19]. In the US, 
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the CDC (2014) approximates that just 40% of diagnosed 
PLWH are retained in care [1]. However, Yehia and col-
leagues suggest that this estimate is too low because 
it only measures the number of kept clinic visits over a 
single year, which neither captures longitudinal trends in 
accessing HIV care nor measures missed clinic appoint-
ments [37]. In reality, PLWH may transition in and out 
of care over time, referred to as “churning,” increasing 
the error margin of a point estimate [3, 4, 37]. Moreover, 
PLWH may be inaccurately designated as “out of care” 
due to undocumented changes in their health provider, 
incarceration, or death [3]. For example, the results of 
a San Francisco-based HIV surveillance project found 
that more than half of the patients who qualified as dis-
engaged from care in local health records had merely 
changed providers [9]. This further illustrates the need 
for coordination among service providers so that data 
reporting can be timely and accurate. This is particularly 
challenging and pertinent for measuring the longitudinal 
estimate of HIV RiC, which is iteratively more complex 
than the dichotomous steps of testing and LTC.
ART adherence
Although an International Association of Physicians in 
AIDS Care (IAPAC) expert committee recommends that 
health providers use patient self-report as a measurement 
of ART adherence, there is no standard indicator for con-
firming that patients consistently stay on ART medica-
tion [7, 8, 38]. Thus, while estimates for the number of 
all PLWH (undiagnosed and diagnosed, regardless of care 
engagement) prescribed ART in the US range from 24 [2] 
to 37% [1], it is unknown how many PLWH are consist-
ently adherent to prescribed regimens. Internationally, 
the US again performs poorly on this measure: adherence 
estimates in other high-income areas range from 44% in 
British Columbia [27] to 66% in Australia [19].
One difficulty with monitoring adherence is that it 
is challenging to measure, as it relies largely on patient 
self-report. To illustrate, the US Medical Monitoring 
Project (MMP) found that 86% of PLWH in medical care 
reported taking ART as prescribed over a period of 3 
days [39]. However, this estimate offers just a snapshot 
of patients’ self-reported adherence patterns, rather than 
a longitudinal record, and must be interpreted with cau-
tion. ART adherence is vital, as it is the primary determi-
nant of viral suppression, which reduces the chance that 
PLWH will transmit the virus by 96% and helps prevent 
the development of ART-resistant strains of the virus [8, 
22, 38, 40].
While the standard HIV care model places ART adher-
ence after the retention stage, Hallett and Eaton suggest 
that a unidirectional model fails to represent other entry 
points into a “leaky” continuum, wherein PLWH are lost 
at each step [41]. In fact, their model predicts that the 
number of PLWH who are at the ART Adherence stage 
is greater than the standard linear model would suggest 
[41]. To explain this contradiction, they suggest that the 
traditional continuum model does not reflect the experi-
ence of PLWH who may reengage in care after dropping 
out of for a period of time, or who may even wait until 
their symptoms have become unmanageable to begin 
ART [41]. Other researchers have similarly proposed that 
PLWH may seek care in an intermittent manner, render-
ing the traditional cascade model too simplistic as an 
individual level monitoring tool [3, 9, 10].
According to an expert panel of the International Asso-
ciation of Physicians.
in AIDS Care, physicians should prescribe ART to 
PLWH immediately after their HIV diagnosis, regard-
less of CD4 count [38]. This is because lower CD4 counts 
weaken the immune system and increase the risk of 
opportunistic infections, AIDS-related diseases, and even 
non-AIDS-related diseases caused by chronic inflamma-
tion [15, 38]. Unfortunately, some countries continue to 
set national threshold guidelines for physicians. In South 
Africa and in many Latin American countries, for exam-
ple, ART prescription protocol dictates that CD4 counts 
must first reach a suboptimal level (e.g., less than 500 
cells per milliliter) [28, 42]. While practices like these are 
often a function of limited resources and are intended 
to prioritize care to PLWH most in need, a recent cost-
benefits analysis indicates that early ART prescription is 
actually more cost-effective, even in low-income coun-
tries where medical resources are limited [43].
Viral suppression
The final step in the continuum is also the primary goal 
of HIV treatment and public health interventions—viral 
suppression through ART. The CDC considers PLWH 
virally suppressed if their most recent viral load, meas-
ured within the past year, is less than 200 copies per mil-
liliter (c/mL) [1]. However, there are an estimated 70% 
of PLWH in the US [1] who are not virally suppressed, 
including both PLWH who are not aware of their infec-
tion status and PLWH who have been diagnosed but are 
not in care. Internationally, not all countries and prov-
inces use the same cutoff for viral suppression, which 
makes comparison more difficult. However, when using 
a more restrictive 50 c/mL as the cutoff, viral suppression 
estimates range from 25% in the US to 62% in Australia 
[19]. Using this comparative method, the US once again 
ranks lowest with respect to HIV outcomes.
Yet, for PLWH who are diagnosed, retained in care, and 
adhering to ART—in other words, PLWH who have com-
pleted each step of the HIV care continuum—90% have 
achieved viral suppression in the US [35]. Recent studies 
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have also demonstrated that simple, cross-sectional 
measures of viral suppression are prone to misclassifica-
tion [44, 45]. As for RiC, viral suppression is not constant 
once achieved, and patients often transition between 
suppressed and non-suppressed states, even over periods 
as short as 1 year.
The updated NHAS has set a goal for increasing the 
proportion of viral suppression among diagnosed PLWH 
to 80% by 2020 [6]. In order to achieve this target, HIV 
providers must work to link and retain PLWH in care. 
Beyond individual health benefits, success in this step 
is vital to success of a test-and-treat strategy, or “treat-
ment as prevention” method, and is vital in preventing 
additional infections [2, 8, 45]. This method has proved 
effective even in rural African countries, where one com-
munity-based HIV testing and counseling intervention 
resulted in a 77% viral suppression rate for participants 
who were retained for a measured one-year period [46].
Healthcare policy and access across the continuum
While many PLWH in the US have become eligible for 
health insurance as a result of the ACA, some HIV pro-
viders have expressed concern that patients will fall out of 
care, especially those who have previously received spe-
cialized services for PLWH through the Health Resources 
and Services Administration (HRSA)’s Ryan White HIV/
AIDS Program (RWHAP) [47, 48]. First created in 1990 
to address what was then termed the “AIDS crisis,” today 
the RWHAP serves over half a million PLWH who are 
either uninsured or underinsured, providing both sup-
portive services (e.g., case management) and direct medi-
cal services (e.g., funding to medical clinics), including 
access to ART via the AIDS Drug Assistance Program 
[48]. Thus, while the ACA provides a tremendous source 
of new and additional coverage, RWHAP will remain a 
valuable “payer of last resort” for low income PLWH [47, 
48], especially in states that have not expanded Medicaid 
to all childless, non-disabled adults under age 65 with 
incomes at or below 138% of the Federal Poverty Level 
[49]. In fact, data from the most recent RWHAP Annual 
Client-Level Data Report [47] indicates that a quarter of 
PLWH in the US still lack health insurance, highlighting 
the need for continued funding of the program. In light 
of the RWHAP’s significant role in providing HIV care to 
PLWH in the US, current literature urges HIV providers 
to advocate for continued funding of RWHAP [50–53], 
which has not been reauthorized since 2013 and relies on 
yearly appropriations from Congress [54].
At the diagnosis stage of the continuum, the US is on 
par with other high-income countries and provinces. 
However, the number of PLWH who are lost to care at 
the LTC stage subsequently positions the US behind 
other countries like Australia and Denmark, and the gap 
widens at each step. Ultimately, this should be a call-to-
action for the US, which excels in HIV testing and diag-
nosis but falls behind other countries with regards to 
care. Until the US addresses all steps in the continuum of 
care, NHAS and UNAIDS goals for 90% viral suppression 
will be unattainable.
Conclusions
The HIV treatment cascade is a straightforward, helpful 
guide for healthcare providers working with PLWH as it 
illustrates snapshot, population-level estimates of succes-
sive steps from diagnosis to viral suppression. Further, 
the IOM, NHAS, CDC, and UNAIDS movements toward 
standardization of national and international quantita-
tive indicators of the cascade’s successive steps facilitates 
measurement, monitoring, and provision of HIV care. 
Yet, even with research-supported national guidelines, a 
large proportion of PLWH are lost from care at each step 
of the cascade in the US. In order to mitigate these losses, 
it is critical to address all steps in the HIV care contin-
uum at an individual-level, most notably the linkage and 
retention stages which have received scant interven-
tion attention [3]. Moreover, as emphasized in the 2020 
NHAS, it is important to strengthen the data coordina-
tion infrastructure so that researchers and providers alike 
have access to instructive patient data that is systematic 
and comparable across geographic jurisdictions and over 
time. This is especially important given that many PLWH 
who gained health insurance through the ACA may have 
changed health providers, increasing the chance that data 
will be lost or incorrectly entered if organizations are not 
vigilant.
Through concerted collaboration, policymakers, HIV 
providers, and other key stakeholders have the ability to 
improve outcomes at each step of the HIV care cascade 
at a population level. The very fact that churning is such 
a frequent feature of HIV care illustrates the complex-
ity of the treatment cascade and of the various individual, 
social, community, and public policy factors that shape 
PLWH’s ability to remain in care, and it highlights the 
importance of maintaining a socioecological perspective 
when addressing the needs of PLWH [55]. While there are 
various pathways to enter and progress through a more 
dynamic continuum at an individual level, the ultimate 
goal remains the same. Sustained viral suppression is the 
key to optimal health outcomes at both the individual and 
population levels, and treatment does serve as preven-
tion. By strengthening outcomes at each step of the HIV 
care continuum, we can move closer to achieving the 
NHAS’ goal of “a future free of new HIV infections in the 
United States and healthier, longer lives for people living 
with HIV” [6]. This domestic goal begins with expanding 
free HIV testing services for people living in every state, 
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in order to facilitate entry into the continuum and prevent 
inadvertent transmission. Further, as global comparison 
data show, the US must vigilantly address LTC strategies, 
as it is at this step in the continuum where the US falls 
behind other high-income regions of the world. For all 
countries, improving outcomes at each stage of the contin-
uum aligns with UNAIDS’ “90–90–90 target” and central 
mission to facilitate a future AIDS-free world. Increasing 
the proportion of PLWH who remain engaged at each step 
of the treatment cascade will help make this goal possible.
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